J. Zalcberg

J. Zalcberg, B. Fischer, R. Stirling, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cell graph neural networks enable the precise prediction of patient survival in gastric cancer

Yu Guang Wang, Guido Montúfar, N. Otter, 2022, npj Precision Oncology.

Neuroendocrine tumours - models for rare tumour management

D. Goldstein, J. Zalcberg, D. L. Chan, 2015 .

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr

S. Sleijfer, J. Blay, S. Litière, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The short to medium term benefits of the Australian colorectal cancer screening program

J. Zalcberg, A. Earnest, S. Ahern, 2020, The Medical journal of Australia.

Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit

J. Zalcberg, A. Heriot, C. H. A. Lee, 2018, International Journal of Colorectal Disease.

Rapid screening for depression – validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients

J. Zalcberg, M. Jefford, L. Mileshkin, 2004, British Journal of Cancer.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

D. Aust, M. Büchler, P. Laurent-Puig, 2017, European journal of cancer.

Review 3 rd St . Gallen EORTC Gastrointestinal Cancer Conference : Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer

D. Aust, M. Büchler, P. Laurent-Puig, 2017 .

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.

I. Seymour, E. Van Cutsem, J. Zalcberg, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does biomodulation of 5-fluorouracil improve results?

R. Herrmann, J. Zalcberg, D. Rischin, 1999, European journal of cancer.

Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial

D. Tu, H. Kennecke, M. Moore, 2007 .

Training general practitioners in flexible sigmoidoscopy to screen for colorectal cancer

J. Zalcberg, J. Martin, B. Crotty, 2001, ANZ journal of surgery.

Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Suzanne G. Orchard, A. Haydon, J. Zalcberg, 2022, Current Oncology Reports.

Recent advances in the treatment of colorectal cancer.

J. Zalcberg, J. Matthews, Michael D. Green, 1992, Australian and New Zealand journal of medicine.

Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity

Jared M. Campbell, J. McNeil, D. Roder, 2017, Clinical genitourinary cancer.

Tools for Predicting Clinical and Patient‐reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity

Jared M. Campbell, J. McNeil, D. Roder, 2017, Clinical genitourinary cancer.

Telehealth models could be extended to conducting clinical trials-a teletrial approach.

J. Zalcberg, S. Sabesan, J. Zalcberg, 2018, European journal of cancer care.

Access to Clinical Trials Closer to Home Using Tele-health

J. Zalcberg, S. Sabesan, 2017 .

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

V. Gebski, A. Barbour, J. Zalcberg, 2022, BMC Cancer.

The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial

M. Southey, J. Zalcberg, B. Jenkins, 2021, Endoscopic ultrasound.

Induction of insulin‐like growth factor binding protein expression by ICI 182,780 in a tamoxifen‐resistant human breast cancer cell line

J. Zalcberg, J. Parisot, L. Bach, 1999, Breast Cancer Research and Treatment.

Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines

I. Marschner, M. Ching, J. Zalcberg, 2004, Cancer Chemotherapy and Pharmacology.

Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3.

I. Marschner, J. Zalcberg, R. Sparrow, 1993, European journal of cancer.

The pure antiestrogen ICI 182,780 binds to a high‐affinity site distinct from the estrogen receptor

R. Sutherland, J. Zalcberg, A. Wakeling, 1995, International journal of cancer.

Tumor-associated antigens--an overview.

J. Zalcberg, I. McKenzie, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour visualisation using a radiolabelled monoclonal antibody.

J. Andrews, M. Lichtenstein, J. Zalcberg, 1983, Australian and New Zealand journal of medicine.

Severe hypoglycaemia after long‐acting octreotide in a patient with an unrecognized malignant insulinoma

S. Dawson, J. Zalcberg, M. Jefford, 2007, Internal medicine journal.

Structure of T cell antigen receptor beta chain in synovial fluid cells from patients with rheumatoid arthritis.

M. Minden, T. Mak, E. Keystone, 1988, Arthritis and rheumatism.

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines

J. Zalcberg, P. Kantharidis, J. Parisot, 2000, Prostate Cancer and Prostatic Diseases.

Localization of human colorectal tumor xenografts in the nude mouse with the use of radiolabeled monoclonal antibody.

J. Andrews, M. Lichtenstein, J. Zalcberg, 1983, Journal of the National Cancer Institute.

A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases.

J. Zalcberg, A. McKenzie, G. Pietersz, 1994, European journal of cancer.

The structure of the T cell gamma chain gene in lymphoproliferative disorders and lymphoma cell lines.

H. Griesser, K. Lennert, M. Minden, 1986, Blood.

Flare Responses in Small Cell Carcinoma of the Lung

J. Zalcberg, W. Cosolo, G. Morstyn, 1988, Clinical nuclear medicine.

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG

V. Gebski, K. Haustermans, F. Lordick, 2017, Annals of Surgical Oncology.

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.

C. Bokemeyer, E. Van Cutsem, R. Goldberg, 2022, European journal of cancer.

Quality of pharmacokinetic research in oncology.

J. Zalcberg, J. Brien, W. Cosolo, 1995, British Journal of Cancer.

Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines.

J. Zalcberg, D. Bell, X. Hu, 1990, Cancer research.

Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].

D. Aust, I. Nagtegaal, K. Haustermans, 2016, European journal of cancer.

Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards

J. Wale, J. Zalcberg, D. Currow, 2021, The Medical journal of Australia.

Recent developments in the systemic therapy of advanced gastroesophageal malignancies

J. Zalcberg, M. Jefford, M. Michael, 2006, Expert opinion on investigational drugs.

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNET

V. Gebski, D. Bailey, N. Pavlakis, 2020 .

Comment on: 'Hospital lung surgery volume and patient outcomes'.

J. Zalcberg, M. Stenger, R. Stirling, 2020, Lung cancer.

'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.

R. Pazdur, J. Zalcberg, D. Cunningham, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)

V. Gebski, K. Haustermans, F. Lordick, 2015, BMC Cancer.

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database.

C. Bokemeyer, E. Van Cutsem, H. Lenz, 2021, Journal of the National Cancer Institute.

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.

J. Zalcberg, M. Millward, D. Rischin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer

J. Zalcberg, M. Amonkar, W. Cheung, 2020, BMC Gastroenterology.

The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer.

J. Kench, N. Merrett, D. Goldstein, 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

P. Francis, J. Zalcberg, M. Millward, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

C. Tournigand, R. Goldberg, V. Heinemann, 2020 .

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

R. Labianca, A. Benson, J. Zalcberg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses

K. Haustermans, B. Nordlinger, M. Mauer, 2016 .

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

R. James, S. Clarke, J. Zalcberg, 2002, European journal of cancer.

Short report Final results of a randomised trial comparing Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

J. Zalcberg, C. Svensson, G. Pérez-Manga, 2005 .

Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer

J. Zalcberg, 1997, Anti-cancer drugs.

First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).

V. Gebski, D. Bailey, N. Pavlakis, 2020 .

Clearing the air: towards agreement about access to high cost cancer medicines.

I. Kerridge, J. Zalcberg, W. Lipworth, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin.

J. Zalcberg, X. Hu, M. de Luise, 1990, European journal of cancer.

Circumvention of doxorubicin resistance in multi-drug resistant human leukaemia and lung cancer cells by the pure antioestrogen ICI 164384.

T. Martin, J. Zalcberg, A. Wakeling, 1991, European journal of cancer.

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

S. Clarke, J. Zalcberg, J. Gutheil, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2018 .

Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17.

D. Tu, M. Moore, J. Zalcberg, 2013 .

Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia.

M. Minden, M. Friedlander, J. Zalcberg, 1986, British Journal of Cancer.

Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy

J. Zalcberg, Michael D. Green, M. Green, 1992, Investigational New Drugs.

Improving regional access: Phase 1 teletrials in the era of COVID‐19

J. Zalcberg, M. Shackleton, G. Gaughran, 2021, Asia-Pacific journal of clinical oncology.

Registry of gastric cancer treatment evaluation (REGATE): II treatment practice

Y. Bang, S. Hitier, J. Zalcberg, 2013, Asia-Pacific journal of clinical oncology.

LBA-06INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial

K. Haustermans, B. Nordlinger, M. Mauer, 2013 .

Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype.

S. Scherer, L. Tsui, M. de Silva, 1999, Cancer genetics and cytogenetics.

The role of chemotherapy in malignant thymoma.

J. Zalcberg, M. Coperchini, 1996, Australian and New Zealand journal of medicine.

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

C. Begley, J. Zalcberg, I. Davis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement o f P latelet R ecovery A fter M yelosuppressive Chemotherapy b y R ecombinant H uman M egakaryocyte Growth a nd D evelopment F actor i n P atients With A dvanced C ancer

Michael R. Green, C. Begley, J. Zalcberg, 2000 .

APPARENT T-CELL NEOPLASMS WITH IMMUNOGLOBULIN GENE REARRANGEMENTS

M. Minden, J. Zalcberg, M. Friedlander, 1985, The Lancet.

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

J. Desai, N. Pavlakis, A. Nagrial, 2022, Targeted Oncology.

Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies

Suzanne G. Orchard, A. Haydon, J. Zalcberg, 2022, British Journal of Cancer.

Monoclonal antibodies to drugs: novel diagnostic and therapeutic reagents.

J. Zalcberg, 1985, Pharmacology & therapeutics.

Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Suzanne G. Orchard, A. Haydon, J. Zalcberg, 2022, Current Oncology Reports.

Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line

L. Campbell, J. Zalcberg, P. Kantharidis, 1994, International journal of cancer.

Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)

Suzanne G. Orchard, P. Gibbs, R. Woods, 2022, medRxiv.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Absolute quantitation of MDR1 transcripts using heterologous DNA standards--validation of the competitive RT-PCR (CRT-PCR) approach.

J. Zalcberg, A. El-Osta, P. Kantharidis, 1999, BioTechniques.

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

R. James, M. Friedlander, J. Zalcberg, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids.

M. de Silva, L. Campbell, J. Zalcberg, 1996, British Journal of Cancer.

Analogues and Cytosine Arabinoside in Myeloid Leukemia Altered Multidrug Resistance Phenotype Caused by Anthracycline

J. Zalcberg, D. Rischin, P. Kantharidis, 2013 .

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.

J. Zalcberg, D. Rischin, P. Kantharidis, 1999, Blood.

Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.

J. Zalcberg, P. Kantharidis, X. Hu, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.

Jared M. Campbell, J. McNeil, D. Roder, 2017, International journal of radiation oncology, biology, physics.

Patient reported outcomes following radiation therapy in men with prostate cancer : a systematic review of prognostic tool accuracy and validity Running title : Radiation therapy PROMS

Jared M. Campbell, J. McNeil, D. Roder, 2017 .

Hormone replacement therapy and breast cancer

J. Zalcberg, J. Siderov, 1998, Medical Journal of Australia.

Characteristics of a breast cancer‐associated antigen defined by RCC‐1 antibody

J. Tjandra, J. Zalcberg, I. Mckenzie, 1990, Immunology and cell biology.

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

P. Hu, D. Tu, J. Zalcberg, 2022, Cancer medicine.

Use of [18F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy

S. Berlangieri, A. Scott, J. Zalcberg, 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

J. Zalcberg, I. Davis, J. Cebon, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Description of a murine B lymphoma tumor-specific antigen.

J. Zalcberg, S. Koch, I. McKenzie, 1984, Journal of immunology.

Not‐for‐resuscitation orders in cancer patients — principles of decision‐making

J. Zalcberg, J. Buchanan, I. Haines, 1990, The Medical journal of Australia.

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

J. Zalcberg, M. IJzerman, F. Macrae, 2022, Scientific Reports.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2014 .

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Robin L. Jones, J. Blay, M. Heinrich, 2022, BMC cancer.

Palliative chemotherapy: a clinical oxymoron

J. Zalcberg, M. Jefford, 2003, The Lancet.

Treatment decision‐making at the end of life: a survey of Australian doctors' attitudes towards patients' wishes and euthanasia

J. Zalcberg, 1997, The Medical journal of Australia.

"Mind the Gap" Revisited.

Michael Wonder, John R Zalcberg, J. Zalcberg, 2017, Seminars in oncology.

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

D. Bowtell, J. Zalcberg, M. Millward, 2006, British Journal of Cancer.

Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.

V. Gebski, J. Zalcberg, Anne Taylor, 2022, The Lancet. Oncology.

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.

R. James, J. Zalcberg, M. Millward, 1999, Seminars in oncology.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

D. Tu, M. Moore, J. Zalcberg, 2015, European journal of cancer.

Hybridomas and monoclonal antibodies: applications in oncology.

J. Zalcberg, I. McKenzie, 1982, The Australian and New Zealand journal of surgery.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes

S. Behar Harpaz, J. Zalcberg, K. Fong, 2022, British Journal of Cancer.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

John R Zalcberg, Michael Michael, Mick Thompson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC).

R. Simes, D. Tu, M. Moore, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

P. Gibbs, D. Tu, M. Moore, 2009, Journal of the National Cancer Institute.

Monoclonal antibodies to drugs--digoxin.

J. Zalcberg, K. Healey, I. McKenzie, 1983, International journal of immunopharmacology.

Chemotherapy in resectable or potentially resectable colon cancer with liver metastases

J. Zalcberg, K. Sjoquist, Z. Samoon, 2022, Expert opinion on pharmacotherapy.

Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation

A. Wolffe, J. Zalcberg, A. El-Osta, 2002, Molecular and Cellular Biology.

Regulation of MDR1 gene expression: emerging concepts.

J. Zalcberg, P. Kantharidis, X. Hu, 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.

J. Zalcberg, A. El-Osta, P. Kantharidis, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Heterogeneity of the human transferrin receptor and use of anti‐transferrin receptor antibodies to detect tumours in vivo

M. Lichtenstein, J. Zalcberg, J. Sullivan, 1987, Immunology and cell biology.

Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer

J. Zalcberg, M. Jefford, M. Michael, 2005, Expert opinion on investigational drugs.

Systemic or Regional Chemotherapy for Liver Metastases from Colorectal Cancer: Has the Wheel Stopped Spinning?

N. Kemeny, J. Zalcberg, 2004, Cancer journal.

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.

S. Clarke, J. Zalcberg, D. Rischin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional Decline in the Cancer Patient: A Review

Suzanne G. Orchard, J. Zalcberg, S. Orchard, 2022, Cancers.

The acceleration of ageing in older patients with cancer.

Suzanne G. Orchard, A. Haydon, J. Zalcberg, 2020, Journal of geriatric oncology.

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

J. Zalcberg, R. Johnstone, A. El-Osta, 2005, Oncogene.

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).

Joon-Oh Park, C. Braconi, J. Zalcberg, 2020, Future oncology.

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

B. Solomon, J. Zalcberg, M. Jefford, 2018, Cancer Chemotherapy and Pharmacology.

Accepting risk in the acceleration of drug development for rare cancers.

David M. Thomas, J. Savulescu, J. Zalcberg, 2015, The Lancet. Oncology.

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

J. Blay, J. Nemunaitis, M. Heinrich, 2019, Future oncology.

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Robin L. Jones, J. Blay, M. Heinrich, 2020, The Lancet. Oncology.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies

J. Zalcberg, K. Field, 2011 .

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Adam Kowalczyk, Robyn Ward, Izhak Haviv, 2005, Cancer research.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Progress in targeted therapies for cancer: overview

B. Solomon, J. Zalcberg, 2008 .

The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.

M. Minden, J. Zalcberg, M. Tweeddale, 1987, Blood.

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

V. Gebski, N. Pavlakis, Y. Bang, 2023, BMC Cancer.

and ) on Activation MDR 1 Gene ( the Methylated Human Multidrug Resistance Protein 2 and Histone Deacetylase 1 from Precipitous Release of Methyl-CpG Binding

A. Wolffe, J. Zalcberg, A. El-Osta, 2002 .

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer

J. Zalcberg, V. Ganju, M. Michael, 2008, British Journal of Cancer.

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

J. Zalcberg, D. Rischin, P. Kantharidis, 1999, British Journal of Cancer.

Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.

A. Cowman, M. Foley, L. Tilley, 1996, Biochemical pharmacology.

An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer

J. Zalcberg, M. Michael, Y. C. Lee, 2015, Expert opinion on investigational drugs.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Rossella Bertulli, Jean-Yves Blay, Ian Judson, 2004, The Lancet.

Liver transplantation in metastatic carcinoid tumour.

P. Angus, J. Zalcberg, M. Coperchini, 1996, Australian and New Zealand journal of medicine.

CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

S. Fox, P. Gibbs, J. Desai, 2020, Clinical & translational immunology.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

A. Bardelli, E. Van Cutsem, D. Tu, 2010, JAMA.

Expression of mdr1 and mrp in the normal B‐cell homologue of B‐cell chronic lymphocytic leukaemia

J. Zalcberg, P. Kantharidis, D. Tzelepis, 1997, British journal of haematology.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

M. Sawyer, D. Tu, M. Moore, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

J. Zalcberg, D. Kee, 2012, Therapeutic advances in medical oncology.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

R. Simes, D. Tu, M. Moore, 2013, British Journal of Cancer.

Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus.

J. Kench, L. Lipton, L. Chantrill, 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Controversies in the management of gastrointestinal stromal tumors

S. Fox, J. Desai, A. Barbour, 2014, Asia-Pacific journal of clinical oncology.

Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator fluo-3.

J. Zalcberg, X. Hu, D. Wall, 1991, Journal of the National Cancer Institute.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

A. D. Van den Abbeele, J. Blay, D. Ettinger, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study.

J. Zalcberg, E. Paul, M. Conron, 2021, Lung Cancer.

Genomic Risk Prediction for Breast Cancer in Older Women

Suzanne G. Orchard, E. Schadt, R. Sebra, 2021, medRxiv.

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ripretinib for the treatment of advanced gastrointestinal stromal tumor

J. Zalcberg, 2021, Therapeutic advances in gastroenterology.

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy

J. Zalcberg, D. Ferraro, 2014, Therapeutic advances in medical oncology.

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

J. Desai, J. Zalcberg, 2012, Asia-Pacific journal of clinical oncology.

Consensus approaches to best practice management of gastrointestinal stromal tumors

S. Fox, J. Desai, D. Goldstein, 2008 .

JNCCN NCCN Task Force Report : Optimal Management of Patients with Gastrointestinal Stromal Tumor ( GIST ) — Update of the NCCN Clinical Practice Guidelines

J. Blay, D. Ettinger, G. Demetri, 2007 .

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

J. Blay, M. van Glabbeke, J. Verweij, 2005, European journal of cancer.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.

J. Zalcberg, M. Millward, M. McKeage, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Advances in Molecular Pathology and Treatment of Periampullary Cancers

N. Merrett, J. Zalcberg, T. Price, 2016, Pancreas.

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

D. Tu, S. Kopetz, H. Kennecke, 2020, Clinical Cancer Research.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

Challenges of international oncology trial collaboration—a call to action

R. Simes, H. Joensuu, J. Zalcberg, 2019, British Journal of Cancer.

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

M. Buyse, E. Saad, J. Zalcberg, 2018, Journal of the National Cancer Institute.

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib

S. Lade, M. Trivett, J. Zalcberg, 2006, Histopathology.

EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy

V. Gebski, D. Goldstein, J. Zalcberg, 2021, Frontiers in Oncology.

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

R. Labianca, M. Büchler, J. Berlin, 2013 .

Patient preference for information about expensive anti-cancer drugs (EACD) that are potential treatment options

J. Savulescu, J. Zalcberg, M. Jefford, 2008 .

Visualization of metastases from colon carcinoma using an lodine 131‐radiolabeled monoclonal antibody

J. Andrews, M. Lichtenstein, J. Zalcberg, 1986, Cancer.

Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

M. Friedlander, J. Zalcberg, M. Michael, 1997, The Medical journal of Australia.

Effect of Aspirin on Cancer Incidence and Mortality in Older Adults

Suzanne G. Orchard, C. Reid, J. McNeil, 2020, Journal of the National Cancer Institute.

Prediction of disability-free survival in healthy older people

Michael S. Warren, H. C. Siew, Suzanne G. Orchard, 2022, GeroScience.

Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial.

Suzanne G. Orchard, C. Reid, P. Gibbs, 2020, Contemporary clinical trials.

Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

B. Solomon, J. Zalcberg, G. McArthur, 2012, BioDrugs.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

D. Tu, J. Zalcberg, J. Simes, 2018, The lancet. Gastroenterology & hepatology.

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

R. Labianca, D. Kerr, P. Johnston, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Do oncologists discuss expensive anti-cancer drugs with their patients?

J. Savulescu, J. Zalcberg, M. Jefford, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, The oncologist.

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.

J. Zalcberg, Shreyaskumar R Patel, 2008, European journal of cancer.

Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework

J. Kench, N. Merrett, Sally E. Green, 2020, BMJ Quality & Safety.

A DJUVANT THERAPY FOR COLORECTAL CANCER

J. Zalcberg, M. Michael, 2014 .

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review

Jared M. Campbell, J. McNeil, D. Roder, 2017, Radiation oncology.

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody

M. Heinrich, C. Corless, J. Zalcberg, 2011, Medical oncology.

The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers

J. Kench, L. Lipton, J. McNeil, 2019, BMJ Open.

Discussing expensive anticancer drugs.

J. Zalcberg, M. Jefford, L. Mileshkin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical paternalism and expensive unsubsidised drugs

J. Savulescu, J. Zalcberg, M. Jefford, 2005, BMJ : British Medical Journal.

Systematic review of the predictors of health service use in pancreatic cancer.

J. Zalcberg, L. Ioannou, L. Te Marvelde, 2022, American journal of cancer research.

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

J. Zalcberg, M. Green, R. Fox, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

R. Thomas, J. Zalcberg, M. Jefford, 2010, British Journal of Cancer.

Clinical utility of ramucirumab in advanced gastric cancer

J. Zalcberg, K. Sjoquist, M. Chan, 2015, Biologics : targets & therapy.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

A. Degramont, J. Meyerhardt, C. Bokemeyer, 2022, JNCI cancer spectrum.

Multiple atypical nevi: a cutaneous marker of germ cell tumors.

J. Grygiel, J. Zalcberg, D. Raghavan, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.

D. Aust, I. Nagtegaal, K. Haustermans, 2016, European journal of cancer.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

C. Fuchs, E. Van Cutsem, J. Tabernero, 2018, Journal of gastroenterology and hepatology.

Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)

S. Clarke, P. Beale, M. Friedlander, 2005 .

Chemotherapy: Metastatic Disease

J. Zalcberg, K. Field, 2010 .

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line

J. Zalcberg, J. Parisot, M. Deluise, 1999, British Journal of Cancer.

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

D. Kerr, L. Seymour, J. Zalcberg, 1998, European journal of cancer.

A case report of oxaliplatin extravasation.

J. Zalcberg, K. Foo, G. Toner, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.

D. Kerr, E. Van Cutsem, J. Zalcberg, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

N. Pavlakis, M. Brundage, D. Tu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review.

N. Merrett, D. Goldstein, J. Zalcberg, 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer

J. Borrás, R. Tollenaar, E. Van Cutsem, 2017, JAMA oncology.

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

J. Zalcberg, M. Millward, R. Gonzalez, 2008, Investigational New Drugs.

Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer.

J. Zalcberg, D. Kissane, S. McLachlan, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis

J. Zalcberg, S. Ahern, R. Stirling, 2021, Health and Quality of Life Outcomes.

What matters most to patients following percutaneous coronary interventions? A new patient-reported outcome measure developed using Rasch analysis

C. Reid, J. McNeil, J. Zalcberg, 2019, PloS one.

Rationale, Opportunities, and Reality of Biosimilar Medications.

J. Zalcberg, 2018, The New England journal of medicine.

Prognostic models to predict survival in patients with pancreatic cancer: a systematic review.

J. Kench, N. Merrett, J. Zalcberg, 2022, HPB : the official journal of the International Hepato Pancreato Biliary Association.

A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

D. Tu, M. Moore, J. Zalcberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?

J. Zalcberg, D. Ball, M. Conron, 2021, ERJ Open Research.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

D. Aust, J. Ajani, M. Ychou, 2012, European journal of cancer.

“A quiet still voice that just touches”: music’s relevance for adults living with life-threatening cancer diagnoses

J. Zalcberg, F. McDermott, B. Daveson, 2014, Supportive Care in Cancer.

V. Gebski, K. Haustermans, F. Lordick, 2015, BMC Cancer.

Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity

J. McNeil, J. Campbell, D. Roder, 2017, Prostate Cancer and Prostatic Diseases.

Towards a strategy for clinical quality registries in Australia.

J. Zalcberg, S. Ahern, S. Evans, 2018, Australian health review : a publication of the Australian Hospital Association.

Serum methotrexate in childhood ALL.

J. Zalcberg, W. Cosolo, J. Siderov, 1992, British Journal of Cancer.

A snapshot of consumer engagement in clinical trials in Australia: results of a national survey of clinical trial networks and research organisations

J. Zalcberg, A. Mckenzie, J. Fallon-Ferguson, 2022, Research Involvement and Engagement.

Medical education in palliative care

J. Zalcberg, I. Haines, A. Zimet, 1990, The Medical journal of Australia.

The role of biological agents in the resection of colorectal liver metastases.

B. Nordlinger, T. Gruenberger, J. Zalcberg, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Hormone replacement therapy and breast cancer: what are the facts?

J. Zalcberg, J. Siderov, 1996, Medical Journal of Australia.

400a – Effect of Initiating Aspirin on Cancer Events in the Healthy Elderly: Primary Results from the Aspree Randomized Controlled Trial

P. Gibbs, J. McNeil, L. Ford, 2019, Gastroenterology.

Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG.

J. Blay, M. van Glabbeke, J. Verweij, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress and challenges in the adjuvant treatment of stage II and III colon cancers

J. Zalcberg, Y. Chua, 2008, Expert review of anticancer therapy.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer.

J. Zalcberg, J. Simes, J. Siderov, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.

J. Zalcberg, M. Jefford, K. Loh, 2015, Clinical colorectal cancer.

Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly.

J. Zalcberg, R. Kefford, J. Matthews, 1992, Seminars in oncology.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.

S. Clarke, J. Zalcberg, M. Millward, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant therapy of colorectal cancer: an overview.

J. Zalcberg, M. Green, A. Wirth, 1991, The Australian and New Zealand journal of surgery.

A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking

J. Zalcberg, M. Stenger, Gavin Wright, 2021, ANZ journal of surgery.

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

M. Namer, J. Bonneterre, J. Zalcberg, 1996, British Journal of Cancer.

1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)

J. Zalcberg, M. Millward, M. Friedlander, 1995 .

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

N. Pavlakis, J. Tie, D. Goldstein, 2019, Journal of Clinical Oncology.

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

R. James, J. Zalcberg, M. Millward, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

G. Ahlenstiel, J. Zalcberg, C. Karapetis, 2022, Hepatology communications.

Sound Continuing Bonds with the Deceased: The Relevance of Music, Including Preloss Music Therapy, for Eight Bereaved Caregivers

J. Zalcberg, F. McDermott, C. O’Callaghan, 2013, Death studies.

Music's Relevance for People Affected by Cancer: A Meta-Ethnography and Implications for Music Therapists.

J. Zalcberg, J. Edwards, F. McDermott, 2016, Journal of music therapy.

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.

R. Labianca, D. Kerr, W. Scheithauer, 2008, Annals of Oncology.

Migraine following the use of a 5-hydroxytryptamine antagonist.

G. Fabinyi, J. Zalcberg, J. Siderov, 1993, Australian and New Zealand Journal of Medicine.

PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis

K. Haustermans, B. Nordlinger, M. Mauer, 2014 .

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

J. Verweij, H. Joensuu, R. Maki, 2015, European journal of cancer.

Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework

Peter Evans, Ashika D Maharaj, Sue M Evans, 2020, PloS one.

Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.

D. Tu, M. Moore, J. Zalcberg, 2023, Journal of Clinical Oncology.

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics

Y. Bang, S. Hitier, J. Zalcberg, 2014, Asia-Pacific journal of clinical oncology.

Recent Advances in the Treatment of Colorectal Cancer

J. Zalcberg, J. Matthews, C. Penfold, 2019, Springer Singapore.

Pancreatic cancer--is the wall crumbling?

J. Zalcberg, Y. Chua, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

M. Heinrich, S. George, J. Zalcberg, 2019, Annals of Oncology.

You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?

J. Zalcberg, A. Sobrero, A. Pastorino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer

M. Friedlander, J. Zalcberg, R. Kefford, 2004, Cancer Chemotherapy and Pharmacology.

Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.

J. Blay, S. Litière, A. Cesne, 2013 .

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.

D. Sargent, M. Buyse, E. Saad, 2017 .

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

C. Tournigand, D. Sargent, M. Buyse, 2014 .

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.

D. Sargent, M. Buyse, J. Hecht, 2014 .

Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide.

J. Zalcberg, J. Siderov, 1994, Anti-cancer drugs.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, Clinical Cancer Research.

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2022, Journal of Clinical Oncology.

O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

J. Blay, M. Heinrich, S. George, 2020 .

INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

N. Pavlakis, Y. Bang, D. Goldstein, 2023, Journal of Clinical Oncology.

Biosimilars are coming: ready or not

J. Zalcberg, 2018, Internal medicine journal.

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.

H. Grabsch, D. Aust, P. Laurent-Puig, 2019, European journal of cancer.

Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials

J. Zalcberg, R. Wolfe, V. Mar, 2021, Asia-Pacific journal of clinical oncology.

Implementation of the Australasian Teletrial Model: Lessons from practice

J. Zalcberg, A. Joshua, J. Sanmugarajah, 2019, Asia-Pacific journal of clinical oncology.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records.

John R Zalcberg, J. Zalcberg, Shannon C Uren, 2013, Journal of oncology practice.

INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)--A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

Overview of controversies in oesophagogastric cancer

J. Zalcberg, K. Sjoquist, A. Cameron, 2011 .

Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia.

D. Roder, J. Zalcberg, K. Fong, 2014, European journal of cancer care.

Comparative effectiveness research — a proposal for a new NHMRC funding stream

J. Zalcberg, 2011, The Medical journal of Australia.

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

J. Zalcberg, M. Jefford, R. Hicks, 2014, British Journal of Cancer.

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones

J. Zalcberg, A. Dobrovic, P. Waring, 2006, Histopathology.

Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis

H. Lenz, D. Tu, J. Zalcberg, 2016, The Pharmacogenomics Journal.

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.

G. Batist, T. Shore, F. Porzsolt, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical issues in euthanasia

J. Zalcberg, J. Buchanan, 1997, The Medical journal of Australia.

Euthanasia: a Clinical Perspective

J. Zalcberg, 1997 .

A qualitative investigation of the supportive care experiences of people living with pancreatic and oesophagogastric cancer

J. Zalcberg, L. Ioannou, D. Croagh, 2022, BMC Health Services Research.

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)

V. Gebski, K. Haustermans, J. Zalcberg, 2012 .

Rectal cancer in Victoria in 1994: Patterns of reported management

S. Lade, J. Zalcberg, J. Millar, 2002, ANZ journal of surgery.

Exploring patient‐reported outcomes following percutaneous coronary intervention: A qualitative study

C. Reid, J. McNeil, J. Zalcberg, 2017, Health expectations : an international journal of public participation in health care and health policy.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.

C. Bokemeyer, E. Van Cutsem, C. Punt, 2021, Journal of the National Cancer Institute.

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

J. Blay, M. van Glabbeke, G. Demetri, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

M. Heinrich, J. Zalcberg, M. Mehren, 2021, Annals of Oncology.

P‐GLYCOPROTEIN EXPRESSION IN CLASSICAL MULTI‐DRUG RESISTANT LEUKAEMIA CELLS DOES NOT CORRELATE WITH ENHANCED CHLORIDE CHANNEL ACTIVITY

R. Kemm, J. Zalcberg, J. D. Parkin, 1994, Clinical and experimental pharmacology & physiology.

Broken doctor–patient relationships: why won't they listen?

J. Zalcberg, M. Jefford, John R Zalcberg, 2014, Medical Journal of Australia.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

V. Gebski, D. Goldstein, J. Zalcberg, 2016, Cancer Chemotherapy and Pharmacology.

The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: where to from here?

J. Zalcberg, M. Michael, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Cell graph neural networks enable digital staging of tumour microenvironment and precisely predict patient survival in gastric cancer

Guido Montúfar, P. Lio’, N. Otter, 2021, medRxiv.

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

V. Gebski, N. Waddell, V. Bonazzi, 2023, Nature communications.

Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward

Kelvin K. W. Chan, A. Adler, J. Zalcberg, 2020, International Journal of Technology Assessment in Health Care.

Colon and rectal cancer treatment patterns and their associations with clinical, sociodemographic and lifestyle characteristics: analysis of the Australian 45 and Up Study cohort

J. Zalcberg, R. Ward, J. Lew, 2023, BMC Cancer.

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.

V. Gebski, D. Bailey, N. Pavlakis, 2022, Journal of Clinical Oncology.

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2023, Journal of Clinical Oncology.

2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC

V. Gebski, K. Haustermans, F. Lordick, 2015 .

Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies.

M. Lichtenstein, J. Zalcberg, M Lichtenstein, 1984, Journal of the National Cancer Institute.

Antitumor effect of somatostatin analogs in neuroendocrine tumors.

D. Goldstein, J. Zalcberg, R. Hicks, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical paternalism and expensive unsubsidised drugs

J. Savulescu, J. Zalcberg, M. Jefford, 2005, BMJ : British Medical Journal.

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

J. Zalcberg, A. Haydon, A. Maciejewska, 2022, ANZ journal of surgery.

Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?

J. Blay, J. Verweij, M. Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, D. Tu, 2012 .

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2020, Journal of Clinical Oncology.

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

D. Tu, J. Zalcberg, J. Simes, 2014 .

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.

K. Howard, J. Zalcberg, D. Zannino, 2014, European journal of cancer.

Soft tissue metastasis of carcinoid tumour: a rare manifestation

J. Zalcberg, J. Slavin, G. Quan, 2004, ANZ journal of surgery.

Outpatient chemotherapy: there's no place like home — sometimes

J. Zalcberg, J. Siderov, M. Petty, 1996, Medical Journal of Australia.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

D. Tu, J. Zalcberg, J. Simes, 2014, Acta oncologica.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Progress and challenges in the adjuvant treatment of stage II and III colon cancers

J. Zalcberg, Y. Chua, 2008, Expert review of anticancer therapy.

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

V. Gebski, D. Goldstein, J. Zalcberg, 2011, European journal of cancer.

D. Goldstein, J. Zalcberg, D. Joseph, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in patients with K‐RAS wild‐type colorectal cancer

D. Tu, M. Moore, H. Au, 2014, Cancer.

Clinical utility of ramucirumab in advanced gastric cancer

J. Zalcberg, K. Sjoquist, M. Chan, 2015, Biologics : targets & therapy.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

E. Van Cutsem, C. Punt, J. Tabernero, 2023, Journal of Clinical Oncology.

Bespoke treatment: Drivers beware!

J. Zalcberg, S. Pattison, 2014, Asia-Pacific journal of clinical oncology.

patients, their families and friends, and for oncologists. We support the initiative of McFarlane et al to aid us in the difficult task of delivering bad news about the cost of medical care.

J. Zalcberg, M. Jefford, L. Mileshkin, 2008 .

Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.

M. Sawyer, D. Tu, M. Moore, 2012 .

Controversies in the management of gastrointestinal stromal tumors

S. Fox, J. Desai, A. Barbour, 2014, Asia-Pacific journal of clinical oncology.

The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).

S. Bates, A. Scott, J. Zalcberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptoms and feelings valued by patients after a percutaneous coronary intervention: a discrete-choice experiment to inform development of a new patient-reported outcome

C. Reid, J. McNeil, R. Norman, 2018, BMJ Open.

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2023, European Journal of Cancer.

O-0017PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER: DISEASE FREE SURVIVAL AT INTERIM ANALYSIS

K. Haustermans, B. Nordlinger, M. Mauer, 2014 .

ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

J. Blay, V. Gebski, H. Joensuu, 2019, Journal of Clinical Oncology.

Serum methotrexate in childhood ALL.

J. Zalcberg, W. Cosolo, J. Siderov, 1992, British Journal of Cancer.

Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.

C. Tournigand, D. Sargent, M. Buyse, 2015 .